| Trucare Inc | |
|
725 Reservoir Ave Ste 103 Cranston RI 02910-4451 | |
| (401) 944-6889 | |
| (401) 944-6726 |
| Full Name | Trucare Inc |
|---|---|
| Speciality | Internal Medicine |
| Location | 725 Reservoir Ave Ste 103, Cranston, Rhode Island |
| Authorized Official Name and Position | Ralph Frank Santoro (OWNER) |
| Authorized Official Contact | 4019446889 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Trucare Inc 725 Reservoir Ave Ste 103 Cranston RI 02910-4451 Ph: (401) 944-6889 | Trucare Inc 725 Reservoir Ave Ste 103 Cranston RI 02910-4451 Ph: (401) 944-6889 |
| NPI Number | 1538659081 |
|---|---|
| Provider Enumeration Date | 05/10/2018 |
| Last Update Date | 09/20/2023 |
| Medicare PECOS PAC ID | 1850646811 |
|---|---|
| Medicare Enrollment ID | O20180614001472 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538659081 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD11412 (Rhode Island) | Primary |
| Provider Name | Joseph P Turner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1447225859 PECOS PAC ID: 8426942715 Enrollment ID: I20040209000837 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Ralph F Santoro |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1710098249 PECOS PAC ID: 9830178912 Enrollment ID: I20040714000758 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Clifford J Fields |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1619901147 PECOS PAC ID: 8325012834 Enrollment ID: I20040927000740 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Shahzad Khurshid |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881754281 PECOS PAC ID: 3577515089 Enrollment ID: I20050214000007 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Andrea N Demers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154395721 PECOS PAC ID: 3375589435 Enrollment ID: I20080816000027 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Vera A Depalo |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1659354546 PECOS PAC ID: 6800946161 Enrollment ID: I20090608000130 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Kathleen L Knowlton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629370309 PECOS PAC ID: 9436337375 Enrollment ID: I20110624000294 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Deirdre O Couture |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871645341 PECOS PAC ID: 1759604960 Enrollment ID: I20141219000237 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Tomoko Snyder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184877953 PECOS PAC ID: 4082973052 Enrollment ID: I20180119001193 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Martha Gargar Charley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609368919 PECOS PAC ID: 2961754940 Enrollment ID: I20181003001487 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Minh Huong M Fay |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144377755 PECOS PAC ID: 9638103930 Enrollment ID: I20181015001938 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Erica Kristen Ogni |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891336293 PECOS PAC ID: 2264864230 Enrollment ID: I20191112002925 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Emily Alves |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215286984 PECOS PAC ID: 1254751100 Enrollment ID: I20201015001227 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
| Provider Name | Jillian L. Degraide |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023885688 PECOS PAC ID: 5092166546 Enrollment ID: I20240109001630 |
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
News Archive
The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs). The document was published in SCAI's official journal, Catheterization and Cardiovascular Interventions.
Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.
Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.
› Verified 1 days ago
Fallon & Horan Do Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1592 Broad St, Cranston, RI 02905 Phone: 401-467-3350 | |
Park Medical Associates, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 251 Park Ave, Cranston, RI 02905 Phone: 800-927-0002 | |
Roberto Ortiz M.d., Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 925 Reservoir Ave, Cranston, RI 02910 Phone: 401-943-9791 Fax: 401-943-1071 | |
Medicine And Long Term Care Associates, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 333 Budlong Rd, Cranston, RI 02920 Phone: 401-943-4530 | |
Knightsville Internal Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1681 Cranston St, Suite D, Cranston, RI 02920 Phone: 401-946-8446 Fax: 401-946-8340 | |
Kardous Primary Care Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1145 Reservoir Ave, Ste 301, Cranston, RI 02920 Phone: 401-946-5001 Fax: 401-946-5101 | |
Leonard A Mannarelli Ii, D.o. Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 135 Atwood Ave, Cranston, RI 02920 Phone: 401-944-1748 Fax: 401-944-1746 |